These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30858217)

  • 1. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
    Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
    Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times.
    Di Pilato V; Ceccherini F; Sennati S; D'Agostino F; Arena F; D'Atanasio N; Di Giorgio FP; Tongiani S; Pallecchi L; Rossolini GM
    Diagn Microbiol Infect Dis; 2020 Feb; 96(2):114901. PubMed ID: 31761480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis.
    Pantel A; Nachar O; Boudet A; Loubet P; Schuldiner S; Cellier N; Sotto A; Dunyach-Remy C; Lavigne JP
    J Antimicrob Chemother; 2021 Jul; 76(8):2057-2060. PubMed ID: 33842980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.
    Fernández J; Greenwood-Quaintance KE; Patel R
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin: a new lipoglycopeptide antibiotic.
    Bailey J; Summers KM
    Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.
    Ramadan MS; Gallo R; Lugarà M; Gambardella M; Oliva G; Bertolino L; Andini R; Coppola N; Zampino R; Durante-Mangoni E
    J Chemother; 2022 Oct; 34(6):360-366. PubMed ID: 34923922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.
    Barnea Y; Lerner A; Aizic A; Navon-Venezia S; Rachi E; Dunne MW; Puttagunta S; Carmeli Y
    J Antimicrob Chemother; 2016 Feb; 71(2):460-3. PubMed ID: 26518048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
    Citron DM; Tyrrell KL; Goldstein EJ
    Diagn Microbiol Infect Dis; 2014 Aug; 79(4):438-40. PubMed ID: 24972854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.